Android Apple

Airway Therapeutics to trial drug for bronchopulmonary dysplasia in newborn babies

By Yahoo! Finance   |   2 months ago
Airway Therapeutics to trial drug for bronchopulmonary dysplasia in newborn babies

Airway Therapeutics, a US biotech company, will conduct a Phase III trial of zelpultide alfa to prevent bronchopulmonary dysplasia in preterm infants. The drug aims to replace a critical lung protein deficiency and enhance immune defense.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.